Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Blockmans

Showing results (91-100 of 145) with videos related to

Pageof 15
Sort By:
Annals of the Rheumatic Diseases|January 27, 2018
Detection of myositis-specific antibodiesJean-Baptiste Vulsteke, Ellen De Langhe, Kristl G Claeys, et al.
Arthritis Research & Therapy|May 22, 2010
Clinical and serological evaluation of a novel CENP-A peptide based ELISAMichael Mahler, Liesbeth Maes, Daniel Blockmans, et al.
Musculoskeletal Care|November 15, 2011
The association of illness perceptions with physical and mental health in systemic sclerosis patients: an exploratory studySeher Arat, Patrick Verschueren, Ellen De Langhe, et al.
Clinical Chemistry and Laboratory Medicine|July 30, 2017
Individual values of antineutrophil cytoplasmic antibodies do not correspond between antigen-specific assaysNiels Rasmussen, Jan Damoiseaux, Elena Csernok, et al.
The Lancet. Rheumatology|January 27, 2024
Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trialJohn H Stone, Jian Han, Martin Aringer, et al.
Journal of Autoimmunity|June 11, 2023
Autoantibodies against the NineTeen complex and U5 RNP in systemic sclerosisJean-Baptiste Vulsteke, Vanessa Smith, Carolien Bonroy, et al.
Rheumatology (Oxford, England)|October 31, 2021
New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extensionJohn H Stone, Helen Spotswood, Sebastian H Unizony, et al.
Clinical Chemistry and Laboratory Medicine|July 30, 2017
PR3-anti-neutrophil cytoplasmic antibodies (ANCA) in ulcerative colitisMichael Mahler, Jan Damoiseaux, Vera Ballet, et al.
Seminars in Arthritis and Rheumatism|December 22, 2016
Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trialKatie Tuckwell, Neil Collinson, Sophie Dimonaco, et al.
Seminars in Arthritis and Rheumatism|April 8, 2021
Detection of multiple myositis-specific autoantibodies in unique patients with idiopathic inflammatory myopathy: A single centre-experience and literature review: Systematic reviewNele Van Horebeek, Jean-Baptiste Vulsteke, Xavier Bossuyt, et al.
Pageof 15

Showing results (91-100 of 145) with videos related to

Sort By:
Pageof 15
Annals of the Rheumatic Diseases|January 27, 2018
Detection of myositis-specific antibodiesJean-Baptiste Vulsteke, Ellen De Langhe, Kristl G Claeys, et al.
Arthritis Research & Therapy|May 22, 2010
Clinical and serological evaluation of a novel CENP-A peptide based ELISAMichael Mahler, Liesbeth Maes, Daniel Blockmans, et al.
Musculoskeletal Care|November 15, 2011
The association of illness perceptions with physical and mental health in systemic sclerosis patients: an exploratory studySeher Arat, Patrick Verschueren, Ellen De Langhe, et al.
Clinical Chemistry and Laboratory Medicine|July 30, 2017
Individual values of antineutrophil cytoplasmic antibodies do not correspond between antigen-specific assaysNiels Rasmussen, Jan Damoiseaux, Elena Csernok, et al.
The Lancet. Rheumatology|January 27, 2024
Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trialJohn H Stone, Jian Han, Martin Aringer, et al.
Journal of Autoimmunity|June 11, 2023
Autoantibodies against the NineTeen complex and U5 RNP in systemic sclerosisJean-Baptiste Vulsteke, Vanessa Smith, Carolien Bonroy, et al.
Rheumatology (Oxford, England)|October 31, 2021
New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extensionJohn H Stone, Helen Spotswood, Sebastian H Unizony, et al.
Clinical Chemistry and Laboratory Medicine|July 30, 2017
PR3-anti-neutrophil cytoplasmic antibodies (ANCA) in ulcerative colitisMichael Mahler, Jan Damoiseaux, Vera Ballet, et al.
Seminars in Arthritis and Rheumatism|December 22, 2016
Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trialKatie Tuckwell, Neil Collinson, Sophie Dimonaco, et al.
Seminars in Arthritis and Rheumatism|April 8, 2021
Detection of multiple myositis-specific autoantibodies in unique patients with idiopathic inflammatory myopathy: A single centre-experience and literature review: Systematic reviewNele Van Horebeek, Jean-Baptiste Vulsteke, Xavier Bossuyt, et al.
Pageof 15